For the year ending 2025-12-31, PCVX has $3,002,717K in assets. $317,207K in debts. $173,959K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 173,959 | |||
| Short-term investments | 1,387,000 | |||
| Prepaid expenses and other current assets | 66,402 | |||
| Total current assets | 1,627,361 | |||
| Property and equipment, net | 257,370 | |||
| Operating lease right-of-use assets | 116,009 | |||
| Long-term investments | 881,664 | |||
| Restricted cash | 1,466 | |||
| Other assets | 118,847 | |||
| Total noncurrent assets | 1,375,356 | |||
| Total assets | 3,002,717 | |||
| Accounts payable | 70,904 | |||
| Accrued compensation | 23,000 | |||
| Accrued contract manufacturing expenses | 74,654 | |||
| Accrued expenses | 31,068 | |||
| Operating lease liabilities current | 6,124 | |||
| Total current liabilities | 205,750 | |||
| Operating lease liabilities long-term | 111,357 | |||
| Other liabilities | 100 | |||
| Total liabilities | 317,207 | |||
| Common stock, 0.001 par value 500,000,000 shares authorized at december31, 2025 and december31, 2024 131,058,858 and 124,893,034 shares issued and outstanding at december31, 2025 and december31, 2024, respectively | 134 | |||
| Additional paid-in capital | 4,838,736 | |||
| Accumulated other comprehensive income (loss) | 1,587 | |||
| Accumulated deficit | -2,154,947 | |||
| Total stockholders' equity | 2,685,510 | |||
| Total liabilities and stockholders' equity | 3,002,717 | |||
Vaxcyte, Inc. (PCVX)
Vaxcyte, Inc. (PCVX)